The Data Is Catching Up to the Movement

Microdosing psilocybin has gone from whispered conversations to dinner table talk, podcast episodes, and wellness routines. However, for a long time, the science hadn't yet caught up to the culture. Millions of people were already experiencing the benefits, sharing breakthroughs in group chats and community circles, while researchers still lacked the data to back up what so many already knew firsthand. That just changed.

A new study published in the journal Addiction puts real numbers behind what many have long suspected, psilocybin microdosing is far more common than previously thought. Drawing on a nationally representative survey of 4,253 U.S. adults, the research offers the most comprehensive picture yet of who is microdosing, how often, and why.

Here’s what we know 👇

🖼️ The Big Picture

An estimated 8.4 million American adults have microdosed psilocybin at least once, and the practice is closely tied to health-seeking behavior rather than recreational use.

Researchers Michelle Priest, Beau Kilmer, Rajeev Ramchand, and Samer Atshan report that: 12.1% of U.S. adults have used psilocybin in their lifetime, and 3.1% used it within the past year.

🚀 Psilocybin Microdosing is More Than Just a “Passing Fad”

With all the recent attention, it’s easy to assume psilocybin microdosing is just another passing trend, something people try briefly before moving on to the next wellness craze.

However, this study shows that assumption is far from the truth. 

Among those who have tried psilocybin, a growing share report microdosing their latest experience, with even higher rates among newer users.

Among lifetime users 26.5% reported microdosing, 57.5% did not, and 14.6% were unsure. 

Among past-year users, 46.9% reported microdosing, 45.6% did not, and just 6.1% were unsure.

Notice the gap. Those who used psilocybin within the past year are more likely to report microdosing than those whose use was further in the past. Among active users, microdosing is now nearly as common as taking a full dose.

It looks like microdosing isn’t going away any time soon. 

👀 Microdosers Aren’t the Regular Partygoer

The study uncovered a clear motivational divide. Compared with those who took full doses:

• Microdosers were 25 percentage points more likely to use psilocybin for mental health reasons 

• 12 percentage points more likely to use it to improve physical health

• 27 percentage points less likely to use it for fun or pleasure

Mental health was the strongest factor distinguishing microdosers from non-microdosers, including those turning to microdosing to address substance use disorders. This goes beyond a simple “mood boost,” “productivity hack,” or “party drug.” For many, it represents a more intentional and meaningful path to recovery.

🍄 Where Do We Go From Here?

This paper provides one of the first nationally representative snapshots of psilocybin microdosing behavior in the United States, a finding that underscores the need for rigorous clinical research to determine whether these perceived benefits hold up under scientific scrutiny. 

However, the implications stretch far beyond the lab. Data like this shapes how policymakers think about psychedelic reform, where research funding gets directed, and how quickly microdosing moves from cultural phenomenon to legitimate therapeutic option. 

The conversation is no longer “Is this happening?” but rather, “What comes next and how do we make sure the people who need this most can access it safely?”

Source: Priest, M., Kilmer, B., Ramchand, R., & Atshan, S. (2026). "Psilocybin microdosing in the United States: Insights from a nationally representative survey." Addiction. 

🎙️ Free Webinar: A New Perspective on Integration with Paul F. Austin & Dr. Dave Rabin

Over time, many in the field have viewed integration coaching as a lower-risk alternative to psychedelic facilitation. The assumption is that supporting someone after a ceremony is inherently safer.

Emerging research and clinical insight suggest the opposite may be true.

The integration period, when the nervous system is most open and adaptable, can also be the most sensitive phase of the entire journey. Without the right framework, this window can carry both meaningful opportunity and real risk.

This is exactly what will be explored in an upcoming free live training, Integration Is the Riskiest Phase (Most Practitioners Don’t Know Why), led by Dr. David Rabin and our co-founder Paul F. Austin. Drawing on decades of combined experience, they will break down how to better recognize signs of true integration, how to identify when a client may be destabilizing, and how to approach post-session support with more clarity and structure.

Monday, April 6th at 10am PT / 1pm ET

🍄 Join our Giving Circle

If you’ve benefited from microdosing, or believe in a future where people can legally and safely access it, we invite you to become a monthly supporter.

Our Giving Circle makes it easy to support microdosing legalization through small, consistent contributions. Giving Circle has partnered with impactful nonprofits like Selena Gomez’s Rare Impact Fund, and we’re grateful for their support as we grow the microdosing movement.

- With love from team Microdosing Collective 🍄

Was this email forwarded? Subscribe to get the next one delivered right to you!

DISCLAIMER: This newsletter is intended for educational and informational purposes only and should not be considered a replacement for professional medical advice. Always consult your healthcare provider before making changes. The Microdosing Collective does not promote the use of any illegal substance. Please be aware that the use, possession, and distribution of psychedelic substances are illegal in many countries and could lead to legal consequences.